ExpreS2ion Biotechnologies
Blood & Organ Banks · Denmark · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Agern Allé 1, Korsholm, North Denmark, 2...Phone Number
+45 22221019Website
www.expres2ionbio.comRevenue
$5.6 MillionIndustry
ZI Rank: 2
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
2
2
2
4
2
About ExpreS2ion Biotechnologies
ExpreS2ion Biotechnologies is a clinical-stage biotechnology company focused on developing innovative vaccines aimed at transforming healthcare and improving quality of life globally. Utilizing their proprietary ExpreS2 protein expression system, they are advancing groundbreaking vaccines to combat infectious diseases and treat cancer. Their lead product, ES2B-C001, is a novel HER2 cancer immunotherapy designed to generate a robust immune response and offer superior tumor inhibition. The company targets healthcare providers and patients in need of effective vaccine solutions.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ExpreS2ion Biotechnologies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if ExpreS2ion Biotechnologies had a recent Job posting/layoffs
Funding: Get notified immidiatlly once ExpreS2ion Biotechnologies has new funding data
Congratulate Masked Content for being promoted to Masked Content at ExpreS2ion Biotechnologies
Website visits: Recent activity has been detected on your website
Check if ExpreS2ion Biotechnologies has recently received funding, and reach out quickly before it becomes old news!
ExpreS2ion Biotechnologies, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if ExpreS2ion Biotechnologies is spiking on competitors!
Earning: See what the market has to say on ExpreS2ion Biotechnologies recently announced quarterly report
Product Launch: Get notified when ExpreS2ion Biotechnologies launches new products
Recommended Actions
Find VP level buyers at ExpreS2ion Biotechnologies
Find 3 more new buyers
Company Profile Activity
Activity Insights
ExpreS2ion Biotechnologies is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
ExpreS2ion Biotechnologies is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about ExpreS2ion Biotechnologies.
ExpreS2ion Biotechnologies financials insights
Gather financial insights about ExpreS2ion Biotechnologies, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Stock Offering
$24.6M
ExpreS2ion Biotechnologies Tech Stack
A closer look at the technologies used by ExpreS2ion Biotechnologies
See more technologies
Most Recent Scoops
Earnings
ExpreS2ion Biotechnologies has reported other operating income of SEK 9.5 million for Q2 2026, up 407% year-on-year, including grant income associated with VICI-Disease CMC subcontracting activities with corresponding costs recognized in R&D expense.
Earnings, Research & Development, Finance
Project
ExpreS2ion Biotechnologies has reported that drug-specific antibody responses were observed in 12 of 13 evaluable patients in the preliminary Phase I dataset for ES2B-C001, with titers increasing across successive dosing visits and remaining elevated at later follow-up, and no safety signals of concern identified to date.
Medical Research, Pharmaceuticals, Clinical Operations
Project
now expects to initiate Phase II development of ES2B-C001 in H2 2027, representing a one-quarter shift from its previous planning assumption, while confirming the end-2026 Phase I readout timeline remains unchanged.
Clinical Operations
Project
ExpreS2ion Biotechnologies has designed influenza antigens for its MucoVax program using ExpreS and glyco-modified cell line technologies, coupled to an antigen-presenting platform, with animal testing and comparison of alternative platforms currently ongoing.
Medical Research, Pharmaceuticals
Project
Medical Research, Pharmaceuticals
ExpreS2ion Biotechnologies News & Media
Warrants of series TO 10 were exercised to approximately 69 percent and ExpreS2ion receives approximately SEK 10 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, RUSSIA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, 6 December 2024 - Today ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") announces the outcoExpreS2ion announces approval to initiate a Phase I clinical trial of ES2B-C001, its novel therapeutic vaccine, being developed for HER2-expressing breast cancer
Hørsholm, Denmark, 2 December 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused portfolio of vaccine candidates targeting infectious diseases and cancer, is proud to announce the approval of its Phase I clinical trial application (CTA) by the Austrian Agency for Health and Food Safety for its novel therapeutic vaccine candidate, ES2B-C001, against HER2-expressing breast cancer. Bent U. Frandsen, CExpreS2ion publishes video presentations from Biostock Life Science Summit and Analysguiden Stora Aktiedagarna
Hørsholm, Denmark, 2 December 2024 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that filmed company presentations in which CEO Bent Frandsen shared insights into the company’s development strategy and value creation potential are now available on the company’s website. The first presentation was delivered at the Biostock Life Science Summit on 21 November 2024. The second took place at the Aktiespararna event Stora Aktiedagarna in StockholmLast day of trading in warrants of series TO 10 in Expres2ion Biotech Holding AB is today, 2 December 2024
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, RUSSIA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, 2 December 2024 - ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") announces that today is t
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ExpreS2ion Biotechnologies
Sign Up For FreeTo access detailed company insights
ExpreS2ion Biotechnologies is a clinical-stage biotechnology company focused on developing innovative vaccines aimed at transforming healthcare and improving quality of life globally. Utilizing their proprietary ExpreS2 protein expression system, they are advancing groundbreaking vaccines to combat infectious diseases and treat cancer. Their lead p... Read More
